Comment on "Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study," by Kahl et al., Cancer Investigation, 2005, 23(1), pp. 13-18.
Smith
Mitchell
M
Borghaei
Hossein
H
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D017239:Paclitaxel / Q000009:adverse effects*
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel